SCM To Support BTG NDA

SCM Pharma will provide scale-up services to BTG for the commercial launch of Varisolve (polidocanol endovenous microfoam (PEM)), a treatment for the appearance and symptoms of varicose veins. SCM has worked with BTG since 2005 assisting with clinical studies, including clinical trial supply for the recent Phase III trial.
 
To date, SCM Pharma has supported BTG with process development, sterile manufacturing, packaging and distribution to trial sites in the U.S. SCM will now be named on the NDA for PEM as a commercial supplier and will further support BTG throughout the NDA review process.  
 
Dianne Sharp, managing director at SCM Pharma, said, “We are very proud to be supporting BTG with its NDA for Varisolve, as it is a product that we have helped them develop for many years. The complexities involved in developing, processing and producing this product illustrates the type of work we do here at SCM Pharma. Working with novel products, difficult processes and applications and often dangerous substances and APIs at relatively smaller scale are very much our sweet spot.”